Combination of Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With Braf v600e-mutates Localised Colon or Upper Rectum Cancer (Neoraf Study)
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Cetuximab (Primary) ; Encorafenib (Primary)
- Indications Adenocarcinoma; Colon cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms NEORAF
Most Recent Events
- 14 Aug 2023 Status changed from not yet recruiting to recruiting.
- 06 Feb 2023 New trial record